SEATTLE, April 28, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutics and vaccines in the areas of oncology and infectious disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will present at the Aegis Capital Emerging Growth Conference on Saturday, April 30. The conference will take place between April 28 and April 30 at the Palazzo Hotel in Las Vegas.
Dr. Wilson will discuss TapImmune's cancer and infectious disease therapeutic development programs including the company's collaborative programs in cancer and biodefence, near term clinical trials and future milestones.
TapImmune's technology is based on reintroducing TAP (Transporters associated with Antigen Presentation), thereby modulating the activity of the antigen processing machinery to increase effective presentation of antigens or markers to the immune system. The immune system can use this information to selectively destroy cancerous cells or those infected with pathogens.
Aegis Capital is a full-service retail and institutional broker-dealer with investment banking that specializes in financial services to companies with high growth potential.
TapImmune's unique approach is designed to increase the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing ('TAP'). Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers which lack normal amounts of TAP.
TapImmune's lead product candidate, AdhTAP, is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is in pre-clinical development of a multi-component vaccine for the treatment of HER-2/neu positive breast cancer.
The Company is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times. TapImmune's TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases. A next generation smallpox vaccine is currently in preclinical development.
The TapImmune Inc. logo is available at
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACT: Glynn Wilson, Chairman & CEO TapImmune Inc. Investor Relations (866) 359-7541